AngioDynamics Q3 2026 Earnings Results and Financial Guidance

This corporate presentation outlines the third-quarter financial results for AngioDynamics for the fiscal year 2026. The company reports an 8.9% increase in total revenue, driven largely by the significant 19% growth within its Med Tech business segment. Key product platforms such as Auryon, AlphaVac, and NanoKnife showed strong commercial momentum, particularly following new regulatory clearances and reimbursement updates. Despite reporting a net loss on a GAAP basis, management highlighted a strengthened balance sheet with zero debt and nearly $38 million in cash. Consequently, the company raised its full-year guidance for net sales and earnings, signaling confidence in its ongoing strategic transition toward high-growth medical technologies. The documents also include non-GAAP reconciliations to provide investors with a clearer view of underlying operational performance.